2. Search Result
Search Result
Results for "

myeloma+cell

" in MedChemExpress (MCE) Product Catalog:

79

Inhibitors & Agonists

2

Peptides

5

Inhibitory Antibodies

8

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-154812
    Gintemetostat

    KTX-1001

    		 Histone Methyltransferase CD44 Cancer
    Gintemetostat (KTX-1001) is an orally active, highly specific NSD2/MMSET histone methyltransferase inhibitor with human NSD2 IC50 values ranging 0.460-2.17 nM and NSD2 SET domain IC50 of 2.32 nM and Kd values ranging 6.3-70.4 nM .Gintemetostat reduces H3K36me2 levels, impairs multiple myeloma cell adhesion and colony formation, enhances cytotoxicity, boosts T-cell activation, and sensitizes resistant multiple myeloma cells to other agents .Gintemetostat can be used for the research of multiple myeloma and relapsed and refractory multiple myeloma .
    Gintemetostat
  • HY-112904
    XRK3F2
    5+ Cited Publications

    		 p62 Autophagy Cancer
    XRK3F2 is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma .
    XRK3F2
  • HY-120400
    KDM5-C70
    5+ Cited Publications

    		 Histone Demethylase Cancer
    KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels .
    KDM5-C70
  • HY-172085
    SH514

    		IFNAR DNA/RNA Synthesis c-Myc CDK Cancer
    SH514 is an orally active IRF4 inhibitor (IC50 = 2.63 μM). SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM). SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX. SH514 effectively inhibits the proliferation of multiple myeloma tumors .
    SH514
  • HY-134582
    dCBP-1
    10+ Cited Publications

    		 PROTACs Epigenetic Reader Domain Cancer
    dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .
    dCBP-1
  • HY-P991155
    Ramantamig

    JNJ-79635322; JNJ-5322

    		 CD3 TNF Receptor Cancer
    Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
    Ramantamig
  • HY-15473
    MLN120B
    Maximum Cited Publications
    28 Publications Verification

    ML120B

    		 IKK Cancer
    MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
    MLN120B
  • HY-100430
    CCF642
    1 Publications Verification

    		 Apoptosis PDI Cancer
    CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity .
    CCF642
  • HY-145757
    Elevenostat
    1 Publications Verification

    JB3-22

    		 HDAC Apoptosis Caspase Cancer
    Elevenostat (JB3-22) is a selective HDAC11 inhibitor with an IC50 of 0.235 µM. Elevenostat can induce apoptosis of multiple myeloma cells and has anti-tumor effect. In addition, Elevenostat inhibits the maturation of mouse oocytes .
    Elevenostat
  • HY-145667
    Biotinylated-JQ1
    1 Publications Verification

    Biotin-JQ1

    		 Epigenetic Reader Domain Cancer
    Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of BRD4. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC50 of 0.4 μM .
    Biotinylated-JQ1
  • HY-P99430
    Alnuctamab

    EM901; CC-93269

    		 CD3 Inflammation/Immunology Cancer
    Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Alnuctamab
  • HY-10406
    Talmapimod
    3 Publications Verification

    SCIO-469

    		 p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Talmapimod (SCIO-469) is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. Talmapimod inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .
    Talmapimod
  • HY-122657
    AI-10-104

    		RUNX Cancer
    AI-10-104 is an inhibitor for runt-related transcription factor (RUNX), which enhances the cytotoxicity in myeloma cells .
    AI-10-104
  • HY-116304
    1G244
    5 Publications Verification

    		 Dipeptidyl Peptidase Apoptosis Cancer
    1G244 is a potent DPP8/9 inhibitor with IC50s of 12 nM and 84 nM, respectively. 1G244 does not inhibit DPPIV and DPPII. 1G244 induces apoptosis in multiple myeloma cells and has anti-myeloma effects .
    1G244
  • HY-101096
    Suvecaltamide

    MK-8998; CX-8998; JZP385

    		 Calcium Channel Neurological Disease Cancer
    Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .
    Suvecaltamide
  • HY-13432
    Nanatinostat
    2 Publications Verification

    CHR-3996

    		 HDAC Apoptosis Cancer
    Nanatinostat (CHR-3996) is a potent, class I selective and orally active HDAC inhibitor with IC50s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat has low activity against HDAC5 (IC50 of 200 nM) and HDAC6 (IC50 of 2100 nM). Nanatinostat induces apoptosis in myeloma cells. Nanatinostat has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .
    Nanatinostat
  • HY-111790
    M3258
    5 Publications Verification

    		 Proteasome Apoptosis Cancer
    M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells .
    M3258
  • HY-147158
    ZXH-1-161

    		Molecular Glues Cancer
    ZXH-1-161 is a potent CRBN modulator that selectively induces the degradation of GSPT1 in a CRBN-dependent manner. ZXH-1-161 can inhibit the proliferation of multiple myeloma cells and exhibits antitumor activity .
    ZXH-1-161
  • HY-P99454
    Azintuxizumab vedotin

    ABBV-838

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
    Azintuxizumab vedotin
  • HY-137984
    Cnicin

    		SARS-CoV Apoptosis Cancer
    Cnicin is an orally bioavailable sesquiterpene lactone. Cnicin has antibacterial and antiproliferative properties and induces apoptosis in primary myeloma cells. Cnicin also exhibits activity against SARS-CoV-2. Cnicin inhibits the viral replication of SARS CoV-2 with an IC50 of 1.18 μg/mL. Cnicin can promote functional nerve regeneration .
    Cnicin
  • HY-141636
    1-PalMitoyl-2-arachidoyllecithin

    1-Palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; PAPC; PC(16:0/20:4)

    		 Endogenous Metabolite Biochemical Assay Reagents Cardiovascular Disease
    1-Palmitoyl-2-arachidonoyl-sn-glycero-3-PC (PAPC) is a phospholipid containing palmitic acid (16:0) and arachidonic acid (20:4) at the sn-1 and sn-2 positions, respectively, that is found in biological membranes. PAPC is oxidized in vivo, and its oxidation products are involved in chronic inflammation and vascular disease. PAPC has been used to study signaling of oxidized phospholipids. Levels of PAPC are decreased in isolated human multiple myeloma cells.
    1-PalMitoyl-2-arachidoyllecithin
  • HY-164099
    LSD1/HDAC6-IN-2

    		HDAC Monoamine Oxidase Histone Demethylase Cancer
    LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma .
    LSD1/HDAC6-IN-2
  • HY-P991183
    SAR-442257

    		CD28 CD38 CD3 Cancer
    SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
    SAR-442257
  • HY-117987
    CPS-11

    N-(Hydroxymethyl)thalidomide

    		 Nuclear Factor of activated T Cells (NFAT) NF-κB Reactive Oxygen Species (ROS) Cancer
    CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines .
    CPS-11
  • HY-178161
    HDAC degrader-2

    		HDAC Apoptosis Cancer
    HDAC degrader-2 is a selective HDAC degrader with a DC50 values of 2.55 μM against HDAC1. HDAC degrader-2 effectively induces the degradation of HDAC1 and HDAC2, but has no significant effect on the degradation of HDAC3, 4, 6 and 8. HDAC degrader-2 exerts potent antiproliferative effects against MM.1S and MCF-7 cells. HDAC degrader-2 induces apoptosis in myeloma cells. HDAC degrader-2 can be used for the study of myeloma .
    HDAC degrader-2
  • HY-157216
    HDAC1 Degrader-1

    		HDAC Cancer
    HDAC1 Degrader-1 (compound 1a) is an HDAC1 degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells .
    HDAC1 Degrader-1
  • HY-171754
    LM-305

    		Antibody-Drug Conjugates (ADCs) Cancer
    LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
    LM-305
  • HY-177740
    BTX306

    		Molecular Glues Apoptosis Caspase Cancer
    BTX306 is a cereblon-targeting molecular glue degrader. BTX306 reduces myeloma cell viability and induces apoptosis. BTX306 overcomes myeloma cell resistance to Lenalidomide (HY-A0003) or Bortezomib (HY-10227). BTX306 is active against primary myeloma cells, and shows efficacy in vivo. BTX306 can be used for myeloma research .
    BTX306
  • HY-P1126
    Dolastatin 15

    DLS 15

    		 Microtubule/Tubulin ADC Payload Apoptosis Cancer
    Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin .
    Dolastatin 15
  • HY-174238
    GSPT1 degrader-7

    		Molecular Glues Cancer
    GSPT1 degrader-7 (Example 43) is a molecular glue degrader targeting GSPT1. GSPT1 degrader-7 has an EC50 of 0.2 nM in DF15 multiple myeloma cells. GSPT1 degrader-7 can be used in the study of cancer .
    GSPT1 degrader-7
  • HY-108420
    INK4C-IN-2
    1 Publications Verification

    		 CDK Cancer
    INK4C-IN-2 is a p18 INK4C inhibitor. NK4C-IN-2 promotes hematopoietic stem cells (HSCs) division by inhibiting INK4C and activating CDK4/6, with an ED50 of 5.21 nM. INK4C-IN-2 shows no cytotoxic to normal 32D cells, HSCs, leukemia cell lines and myeloma cell lines .
    INK4C-IN-2
  • HY-N16392
    14-epi-Berkeleylactone F

    		Endogenous Metabolite Infection
    14-epi-Berkeleylactone F (Compound 8) is a C-14 epimer of Berkeleylactone F (HY-N8386). 14-epi-Berkeleylactone F can be isolated from Penicillium turbatum NRRL 5630. 14-epi-Berkeleylactone F has no significant biological activity against bacterium (Staphylococcus aureus, Bacillus subtilis and E. coli), fungi Candida albicans, the parasite Giardia duodenalis and NS-1 murine myeloma cells .
    14-epi-Berkeleylactone F
  • HY-13312A
    GTx-134

    		IGF-1R Insulin Receptor Akt Apoptosis Cancer
    GTx-134 is a dual insulin-like growth factor 1 receptor/insulin receptor (IGF-1R/IR) inhibitor with an IC50 values for IGF-1R and IR of 97 and 187 nM respectively. GTx-134 inhibits the autophosphorylation of IGF-1R and its downstream signaling pathway (Akt), thereby blocking the proliferation and survival signals of tumor cells. GTx-134 has broad-spectrum inhibitory activity against multiple myeloma cell lines and can induce apoptosis in sensitive cells. GTx-134 significantly inhibits tumor growth in mice with MM1.S cell transplantation. GTx-134 works in synergy with existing therapies (such as protease preparations, immunomodulators). GTx-134 can be used in high-risk myeloma research .
    GTx-134
  • HY-131958
    D942

    		AMPK Cancer
    D942 is a cell penetrant AMPK activator and partially inhibits the mitochondrial complex I. In multiple myeloma cells, D942 inhibits cell growth .
    D942
  • HY-15901
    LGB321

    		mTOR Cancer
    LGB321 is an inhibitor of PIM2-dependent multiple myeloma cell lines, effectively inhibiting proliferation and key signaling pathways such as mTOR-C1 and phosphorylation of BAD .
    LGB321
  • HY-N15480
    Nanangenine C

    		Bacterial Cancer
    Nanangenine C is a drimane sesquiterpene that has been found in Aspergillus. It is active against B. subtilis (IC50 = 5.7 μg/ml) and cytotoxic to NS-1 mouse myeloma cells (IC50 = 4.1 μg/ml).
    Nanangenine C
  • HY-134262
    8-Bromo-ATP

    8-Bromoadenosine 5'-triphosphate; 8-Br-ATP

    		 P2X Receptor Cancer
    8-Bromo-ATP (8-Bromoadenosine 5'-triphosphate), an ATP analogue, is a purinergic P2X receptor agonist. 8-Bromo-ATP shows cytotoxic to multiple myeloma cells with an IC50 of 23.1 μM .
    8-Bromo-ATP
  • HY-15473A
    MLN120B dihydrochloride
    Maximum Cited Publications
    28 Publications Verification

    ML120B dihydrochloride

    		 IKK Inflammation/Immunology Cancer
    MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
    MLN120B dihydrochloride
  • HY-150595
    HDAC6-IN-10

    		HDAC Microtubule/Tubulin Cancer
    HDAC6-IN-10 is a highly selective HDAC6 inhibitor with the IC50 of 0.73 nM. HDAC6-IN-10 has 144~10941-fold selectivity over other HDAC isoforms. HDAC6-IN-10 shows anti-proliferative activities against multiple myeloma cells .
    HDAC6-IN-10
  • HY-117087
    K103

    		Phosphatase PANoptosis Cancer
    K103 is an inhibitor discovered from the screen that is an analog of the serotonin antagonist benzazocine. K103 exhibited inhibition of SHIP homologues, labelling it a pan-SHIP1/2 inhibitor, but the molecule had no effect on another 5' inositol phosphatase, OCRL. In line with the "two PIPs hypothesis", the molecule exhibited significant anti-tumour effects against a variety of cell lines, particularly breast cancer cells. Additional studies with K103 revealed that inhibition of SHIP1/2 in multiple myeloma cells resulted in G2/M cell cycle arrest followed by extensive apoptosis via activation of the caspase cascade. K103 fits the commonly used small molecule agent property profile, but while this work was being conducted, it was discovered that K103 caused psychoactive effects in mice, which limited the utility of the molecule in vivo. Therefore, certain synthetic studies were conducted on this tryptamine to identify the features that needed to be present in the molecule to maintain pan-SHIP1/2 inhibition in order to design an inhibitor with favourable pharmacodynamic properties and an improved side effect profile.
    K103
  • HY-172368
    PROTAC CARM1/IKZF3 degrader-1

    		PROTACs Histone Methyltransferase IKZF Family Apoptosis Inflammation/Immunology Cancer
    PROTAC CARM1/IKZF3 degrader-1 (Compound 074) inhibits CARM1, reduces the methylation level of its substrate BAF155. PROTAC CARM1/IKZF3 degrader-1 is the PROTAC degrader for IKZF 1/3 through a CRBN-dependent pathway. PROTAC CARM1/IKZF3 degrader-1 inhibits the expression of MYC protein, thereby inhibiting the proliferation of a variety of multiple myeloma cells. PROTAC CARM1/IKZF3 degrader-1 induces apoptosis in cell H929. PROTAC CARM1/IKZF3 degrader-1 overcomes immunomodulatory drugs (IMiD, such as pomalidomide) resistance. PROTAC CARM1/IKZF3 degrader-1 can be used in cancer and immunology research . (Pink: ligand for target protein CARM1/IKZF3 ligand 1 (HY-172369); Active form of target protein ligand: EZM 2302 (HY-111109); Black: linker (HY-21999); Blue: ligand for E3 ligase Cereblon Thalidomide 4-fluoride (HY-41547))
    PROTAC CARM1/IKZF3 degrader-1
  • HY-117520
    FV-162

    		Proteasome Cancer
    FV-162 is a potent, orally active and irreversible proteasome inhibitor. FV-162 exhibits cytotoxic to human myeloma cell lines and primary myeloma cells. FV-162 inhibits tumor growth in a myeloma xenograft mouse model. FV-162 can be used for myeloma research .
    FV-162
  • HY-125490
    Shermilamine B

    Debromoshermilamine A

    		 Others Cancer
    Shermilamine B, a pyridoacridine alkaloid, exhibits potent anticancer activity in multiple myeloma cell lines .
    Shermilamine B
  • HY-161474
    Antiproliferative agent-50

    		Drug Isomer Cancer
    Antiproliferative agent-50 (Compd VIII-a) is an inhibitor of myeloma cell proliferation and may be used to inhibit multiple myeloma .
    Antiproliferative agent-50
  • HY-163334
    GGDPS-IN-1

    		Ras Cancer
    GGDPS-IN-1 (Compound 37) is a geranylgeranyl diphosphate synthase (GGDPS) inhibitor with an IC50 of 49.4 nM. GGDPS-IN-1 disrupts protein geranylgeranylation in myeloma cells .
    GGDPS-IN-1
  • HY-122467
    Kumbicin C

    		Bacterial Infection Cancer
    Kumbicin C is a bis-indolyl benzenoid compound from an Australian soil fungus, Aspergillus kumbius. Kumbicin C inhibits the growth of mouse myeloma cells and the Gram-positive bacterium Bacillus subtilis .
    Kumbicin C
  • HY-125092
    Drimentine C

    		Antibiotic Infection
    Drimentine C is a terpenylated diketopiperazine antibiotic originally isolated from Actinomycete bacteria. It inhibits proliferation of NS-1 murine β lymphocyte myeloma cells by 63 and 98% in vitro when used at concentrations of 12.5 and 100 μg/mL, respectively.
    Drimentine C
  • HY-173394
    hCAIX/XII-IN-15

    		Carbonic Anhydrase Apoptosis Cancer
    hCAIX/XII-IN-15 (Compound 17β) is an inhibitor of hCA IX and hCA XII, with Kis of 0.42 and 4.37 μM respectively. hCAIX/XII-IN-15 has pro-apoptotic effect in multiple myeloma cells .
    hCAIX/XII-IN-15
  • HY-118079
    Drimentine B

    		Endogenous Metabolite Infection
    Drimentine B is a terpenylated diketopiperazine originally isolated from Actinomycete bacteria that has anticancer activity. It inhibits the proliferation of NS-1 murine β lymphocyte myeloma cells by 41 and 59% in vitro when used at concentrations of 50 and 100 μg/mL, respectively.
    Drimentine B
  • HY-169051
    SIRT-IN-5

    		Sirtuin Cancer
    SIRT-IN-5 is a SIRT3 inhibitor, with an IC50 value of 2.88 μM. SIRT-IN-5 can promote the differentiation of multiple myeloma cells, along with an increase in the expression of the differentiation antigen CD49e and human immunoglobulin light chains λ and κ .
    SIRT-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: